ABO-mismatched renal transplantation

Ther Apher. 1998 Nov;2(4):308-10.

Cryofiltration apheresis for major ABO-incompatible kidney transplantation.
Tamaki T, Tanaka M, Katori M, Osanai M, Yasuhara M, Meguro J, Kukita K, Yonekawa M, Kawamura A.

Transplantation. 2007 Dec 27;84(12 Suppl):S4-7.

Japanese experience of ABO-incompatible living kidney transplantation.
Tanabe K.

Focal glomerulosclerosis

Am J Transplant. 2003 Nov;3(11):1459.

Immunoadsorption with tryptophan adsorbers for successful treatment of late steroid-refractory recurrent focal glomerulosclerosis.
Beige J, Perez-Canto A, Moosmayer I, Offermann G, Zidek W, Klingel R.

Inflammatory bowel disease (IBD)

Current Pharmaceutical Design 2003; 9 307-21

Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column.
Sawada K, Muto T, Shimoyama T, Satomi M, Sawada T, Nagawa H, Hiwatashi N, Asakura H, Hibi T.

J Gastroenterol. 2003;38(7):684-9.

Poorly controlled ulcerative colitis treated by colectomy during remission induced by extracorporeal leukocyte removal therapy.
Fukunaga K, Fukuda Y, Sawada K, Hori K, Matoba Y, Sagayama K, Ohnishi K, Fukui S, Shimoyama T.

J Gastroenterol. 2003 Mar;38 Suppl 15:51-4.

Leukocytapheresis for treatment of IBD.
Kohgo Y, Ashida T, Maemoto A, Ayabe T.

Ther Apher. 2002 Dec;6(6):402-12.

Fluctuations in the peripheral blood leukocyte and platelet counts in leukocytapheresis in healthy volunteers.
Yamaji K, Yang K, Tsuda H, Hashimoto H.

J Clin Apheresis. 2001;16(2):74-81.

Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis.
Hidaka T, Suzuki K, Kawakami M, Okada M, Kataharada K, Shinohara T, Takamizawa-Matsumoto M, Ohsuzu F.

Dis Colon Rectum. 2003; 46 Suppl: S66-77.

Leukocytapheresis as an adjunct to conventional medication
for inflammatory bowel disease.
Sawada K.

J Gastroenterol. 2004 Dec;39(12):1150-7.

Suppression of interleukin-1beta- and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis.
Andoh A, Ogawa A, Kitamura K, Inatomi O, Fujino S, Tsujikawa T, Sasaki M, Mitsuyama K, Fujiyama Y.

J Clinic Apheresis 2005;20(1), Abs 4.

Leukocytapheresis (LACP) for chronic active ulcerative colitiss - final results of a pilot trial and design of the german randomized, double-blind, placebo-controlled multicenter trial (MICELL-UC trial)
Klingel R, Emmrich J, Ramlow W, Mausfele-Lafdhiya P.

Am J Gastroenterol. 2005 Jun;100(6):1362-9.

Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment.
Sawada K, Kusugami K, Suzuki Y, Bamba T, Munakata A, Hibi T, Shimoyama T.

Dig Dis Sci. 2005 Apr;50(4):767-73.

Leukocytapheresis (LCAP) for management of fulminant ulcerative colitis with toxic megacolon.
Sawada K, Egashira A, Ohnishi K, Fukunaga K, Kusaka T, Shimoyama T.

Ther Apher Dial. 2006 Feb;10(1):54-8.

Leukocytapheresis for ulcerative colitis: a comparative study of anticoagulant (nafamostat mesilate vs. dalteparin sodium) for reducing clinical complications.
Ashizuka S, Nishiura R, Ishikawa N, Yamaga J, Inatsu H, Fujimoto S, Eto T.

Inflamm Bowel Dis. 2006 Jan;12 Suppl 1:S15-21.

Preliminary data on the use of apheresis in inflammatory bowel disease.
Sandborn WJ

Ther Apher Dial. 2008 Dec;12(6):484-90.

Multivariate analysis for factors predicting rapid response of leukocytapheresis in patients with steroid-resistant ulcerative colitis: a multicenter prospective open-label study.
Matsumoto T, Andoh A, Okawa K, Ito H, Torii A, Yoshikawa S, Nakaoka R, Okuyama Y, Oshitani N, Nishishita M, Watanabe K, Fukunaga K, Ohnishi K, Kusaka T, Yokoyama Y, Sasaki M, Tsujikawa T, Aoki T, Kusaka T, Takeda Y, Umehara Y, Nakamura S, Fujiyama Y.

Inflamm Bowel Dis. 2008 Oct;14(10):1466-7.

Leukocytapheresis in a girl with severe ulcerative colitis refractory to corticosteroids, infliximab, and cyclosporine A.
Dittrich K, Richter M, Rascher W, Köhler H.

Ther Apher Dial. 2008 Aug;12(4):271-7.

Mobilization of bone marrow cells by leukocytapheresis in patients with ulcerative colitis.
Mitsuyama K, Andoh A, Masuda J, Yamasaki H, Kuwaki K, Takedatsu H, Seki R, Nishida H, Tsuruta O, Sata M.

Curr Pharm Des. 2009;15(18):2110-9.

Recent understanding of leukocytapheresis (LCAP) for the treatment of inflammatory bowel disease.
Mitsuyama K, Yamasaki H, Kuwaki K, Takedatsu H, Sata M.

Cytotherapy. 2009;11(2):229-37.

Therapeutic leukocytapheresis in inflammatory bowel disease: clinical efficacy and mechanisms of action.
Mitsuyama K, Sata M.

J Clin Apher. 2010;25(5):287-93.

Safety and tolerability of a modified filter-type device for leukocytapheresis using ACD-A as anticoagulant in patients with mild to moderately active ulcerative colitis. Results of a pilot study.
Muratov V, Lundahl J, Mandic-Havelka A, Elvin K, Ost A, Shizume Y, Furuya K, Löfberg R.

Transfus Apher Sci. 2011;44(2):113-7.

A multicenter study of the efficacy and safety of leukocytapheresis therapy without concomitant systemic steroid treatment in patients with active ulcerative colitis.
Ashida T, Kohgo Y, Munakata A, Noguchi M, Iizuka B, Endo Y, Hanai H, Yoshikawa T, Matsumoto T, Aoyama N, Matsui T, Mitsuyama K, Hibi T.

Bilirubin

Int J Artif Organs. 2004 Aug;27(8):717-22.

Bilirubin-adsorption in 23 critically ill patients with liver failure.
Senf R, Klingel R, Kurz S, Tullius S, Sauer I, Frei U, Schindler R.

Transplant Proc. 2007 Jul-Aug;39(6):1904-6.

Selective bilirubin removal by plasma treatment with Plasorba BR-350 for early cholestatic graft dysfunction.
Adani GL, Lorenzin D, Currò G, Sainz-Barriga M, Comuzzi C, Bresadola V, Avellini C, Baccarani U.

HCV

Transplantation, 2006 June 27;81(12):1747-9

Impact of double filtration plasmapheresis in combination with interferon and ribavirin in living donor liver transplant recipients with Hepatitis C.
Masahiko Taniguchi, Hiroyuki Furukawa, Tsuyoshi Shimamura, Tomomi Suzuki, Kenichiro Yamashita, Minoru Ota , Satoru Todo

Hepatology Research 2007 Sep;37(9):701-710

Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load.
Kenji Fujiwara, Shuichi Kaneko, Shinichi Kakumu, Michio Sata, Shuhei Hige, Eiichi Tomita, Satoshi Mochida and The Virus Reduction Therapy Study Group

Hepatol Res. 2010 Nov;40(11):1072-1081.

Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C.
Kaneko S, Sata M, Ide T, Yamashita T, Hige S, Tomita E, Mochida S, Yamashita Y, Inui Y, Kim SR, Komada N, Mikami T, Satoh S, Morita S, Takaguchi K, Hirashima N, Nishio Y, Watanabe D, Kioka K, Fujiwara K.